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Abstract
Background: Acute encephalitis syndrome (AES) is commonly seen among hospitalized Nepali children. Japanese
Encephalitis (JE) accounts for approximately one-quarter of cases. Although poor prognostic features for JE have
been identified, and guide management, relatively little is reported on the remaining three-quarters of AES cases.
Methods: Children with AES (n = 225) were identified through admission records from two hospitals in
Kathmandu between 2006 and 2008. Patients without available lumbar puncture results (n = 40) or with bacterial
or plasmodium infection (n = 40) were analysed separately. The remaining AES patients with suspected viral
aetiology were classified, based on positive IgM antibody in serum or cerebral spinal fluid, as JE (n = 42) or AES of
unknown viral aetiology (n = 103); this latter group was sub-classified into Non-JE (n = 44) or JE status unknown
(n = 59). Bad outcome was defined as death or neurological sequelae at discharge.
Results: AES patients of suspected viral aetiology more frequently had a bad outcome than those with bacterial or
plasmodium infection (31% versus 13%; P = 0.039). JE patients more frequently had a bad outcome than those with
AES of unknown viral aetiology (48% versus 24%; P = 0.01). Bad outcome was independently associated in both JE and
suspected viral aetiology groups with a longer duration of fever pre-admission (P = 0.007; P = 0.002 respectively) and
greater impairment of consciousness (P = 0.02; P < 0.001). A higher proportion of JE patients presented with a focal
neurological deficit compared to patients of unknown viral aetiology (13/40 versus 11/103; P = 0.005). JE patients
weighed less (P = 0.03) and exhibited a higher respiratory rate (P = 0.003) compared to Non-JE patients.
Conclusions: Nepali children with AES of suspected viral aetiology or with JE frequently suffered a bad outcome.
Despite no specific treatment, patients who experienced a shorter duration of fever before hospital admission
more frequently recovered completely. Prompt referral may allow AES patients to receive potentially life-saving
supportive management. Previous studies have indicated supportive management, such as fluid provision, is
associated with better outcome in JE. The lower weight and higher respiratory rate among JE patients may reflect
multiple clinical complications, including dehydration. The findings suggest a more systematic investigation of the
influence of supportive management on outcome in AES is warranted.
Background
Acute encephalitis syndrome (AES) is a constellation of
clinical signs and/or symptoms, i.e. acute fever, with an
acute change in mental status and/or new onset of sei-
zures [1]. These clinical signs suggest the patient has
acute inflammation of the brain and are used by clini-
cians to identify patients with acute encephalitis. Viruses
are regarded as the most important cause of the acute
encephalitis syndrome worldwide. However, the syn-
drome can be associated with a range of pathogens,
including acute bacterial or parasitic infection. Where
population based studies have been undertaken, the inci-
dence ranges between 3.5 and 7.4 cases per 100,000
patient-years [2]. Acute encephalitis can be associated
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ness, seizures, limb paresis or death [3].
In Asia, the major identified cause of acute encephalitis
is Japanese Encephalitis (JE) virus. JE affects over 50,000
people annually, leading to 8-30% mortality and 50-60%
disability, with children bearing the brunt of the disease
burden [1,4-6]. JE is associated with considerable mortality
and morbidity among Nepali children [3]. Consequently,
the Ministry of Health and Population of Nepal, supported
by the office of Infection Prevention Division, World
Health Organisation (WHO), has integrated JE surveil-
lance with Acute Flaccid Paralysis, Neonatal Tetanus and
Measles in its National surveillance network since 2004
[7]. Over 23,000 cases of AES and 2500 cases of JE have
been reported by the WHO surveillance network since
2004 (personal communication: Mr Tika Sedai, Data Man-
ager, Programme for Immunization Preventable Diseases,
WHO, Kathmandu, Nepal).
In Nepal, like many countries throughout Asia, test
results for JE are often not available until weeks after the
patient presents to the health care centre, because they are
performed in a centralized government facility. Conse-
quently, health care workers attempt to distinguish JE
from other causes of AES based on the patient’s clinical
features, so that they can focus attention on known com-
plications, such as seizures, and avoid unnecessary treat-
ments, such as antibiotics. However, this approach can be
inaccurate, leading to sub-optimal or inappropriate man-
agement. There have been several publications relating
admission clinical parameters to outcome among JE cases,
and the identification of poor prognostic indicators has
helped focus attention on treatable complications of infec-
tion [8-10]. However, relatively little work has been done
identifying prognostic features among the Non-JE AES
patients. We therefore decided to investigate for diagnostic
and prognostic features that distinguish between JE and
other causes of AES, in a retrospective review of all chil-
dren with AES at two hospitals in Kathmandu, Nepal.
Methods
The hospital records of all children, aged 1 - 14 years, pre-
senting either to Kanti Children’sH o s p i t a l ,M a h a r a j g u n j ,
Kathmandu, Nepal or Patan Hospital, Lalitpur, Nepal,
from January 2006 to January 2008 were screened for a
history consistent with acute encephalitis syndrome (AES).
Kanti Children’s Hospital is a busy tertiary level referral
centre. It has 300 beds and provides health care services to
300-400 children per day. Patan Hospital is a general hos-
pital situated at the southern end of Kathmandu. It has
450 beds and provides health services to around 1,000
people per day, predominantly adults.
The hospital notes were examined by qualified paediatri-
cians employed within the respective hospitals. Relevant
clinical features and laboratory parameters present at
admission were recorded in a standardized proforma. Each
proforma was designated a unique study number. Study
data were transcribed from the proforma to the study
database. The study number was used to access the data
for all future data analyses.
The study was approved by the Instituitional Review
Committee of Kanti Children’s Hospital and Patan Hos-
pital, Kathmandu, ethical committee of the Nepal Health
Research Council, Kathmandu and the Ethical Review
Committee of the Liverpool School of Tropical Medicine,
Liverpool, UK.
Acute encephalitis syndrome (AES) and Japanese
encephalitis (JE) case definitions
The classification of AES was based on the World Health
Organization’s (WHO) definition [1]. The results of the JE
testing, undertaken as part of the JE surveillance pro-
gramme, were related to the identified cases. The AES
cases, based on the results of their microbiological and
serological tests, were classified as AES of suspected viral
aetiology (Confirmed JE, Non-JE and JE Status unknown)
and AES of non-viral aetiology (AES-bacterial or parasitic
aetiology). The clinical features within each class were
examined. Cases definitions were as follows:
￿ AES: Fever or recent history of fever with change in
mental status (including confusion, disorientation,
coma, or inability to talk) and/or new onset of seizures
(excluding simple febrile seizures). Other early clinical
findings could include an increase in irritability, som-
nolence or abnormal behaviour greater than that seen
with usual febrile illness [1,3].
￿ AES of suspected viral aetiology: was defined by ful-
filling the definition for AES (above) and having a dis-
charge diagnosis of suspected viral encephalitis or
menigo-encephalitis, supported by a CSF cell count <
1000 cells/mm
3 with a lymphocyte predominance and
no positive identification of non-viral pathogens (e.g.
bacteria or parasites) in the CSF or blood [3,11].
￿ Confirmed JE: A suspected case which is shown to
have IgM antibodies (≥ 40 units) specific to JE virus in
a single (CSF and/or serum) sample (or a rise in titres
among paired samples) as detected by IgM-capture
ELISA (see testing below).
￿ Non-JE: A suspected viral case which is shown to
have an absence of IgM antibodies specific to JE virus
based on a negative test for a single sample collected
after the ninth day of illness or no change in titres in
paired samples collected at least seven days apart.
￿ JE Status unknown: A suspected viral case which
w a se i t h e rn o tt e s t e df o ra n t i - J EI g Ma n t i b o d i e so r
had samples tested that were collected too early in
illness course to confidently rule out JE (as defined
above).
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case which was not confirmed as JE; this group
included both of the categories described above, i.e.
Non-JE, and JE Status unknown.
￿ AES of non-viral aetiology: was defined by fulfilling
the definition for AES (above) and either; (a) having a
documented discharge diagnosis of suspected bacterial
meningitis or meningo-encephaltis, supported by a
CSF cell count > 1000 cells/mm
3 or a pleocytosis with
a polymorph predominance and a raised CSF protein
(> 0.45 g/L) [3,11]; or (b) having a positive identifica-
tion of non-viral pathogen in CSF or blood. A positive
identification of a non-viral pathogen was fulfilled by a
positive Gram stain or bacterial culture from CSF; a
positive bacterial culture from blood; a positive Widal
test for Samonella typhi [1,4]; or observation of asexual
Plasmodium falciparum parasites in peripheral blood
smears [4,6].
Other clinical definitions
Outcome at discharge was classified as good or bad. Good
outcome was defined as being alive with no impairment of
consciousness or neurological sequelae. Bad outcome was
defined by death or neurological sequelae at discharge.
Patients that self-discharged or were referred to another
hospital prior to discharge were excluded from outcome
analysis.
Neurological sequelae were defined by the presence of
one or more of the following at discharge; impaired con-
sciousness, weakness (monoparesis hemiparesis, quadripar-
esis), focal or generalized abnormal limb tone (hypertonia,
hypotonia), focal or generalized abnormal limb reflexes
(hypereflexia, hyporeflexia), diagnosis of new onset or
recurrent seizures or new or recurrent extra pyramidal
movement disorders [5].
JE diagnostic test
JE virus exposure was tested by MAC-ELISA (IgM anti-
body capture-Enzyme Linked Immunosorbent Assay). The
ELISA plates were supplied by the Armed Forces Research
Institute of Medical Sciences (AFRIMS), Bangkok, Thai-
land [12]. ELISA measurements were undertaken follow-
ing the protocol supplied by AFRIMS. Diluted patient sera
(1:100) or CSF (1:10) were added to the plates. Absorbance
of experimental, positive and negative control samples
were measured in duplicate in 96-well plates using a
micro-titre plate reader (HumaReader Single Plus, Human
GmbH, Wiesbaden, Germany). Single experimental
patient samples with a mean absorbance ≥ 40 units (fol-
lowing subtraction of the absorbance for the negative con-
trols) were considered positive. External quality assurance
was undertaken by AFRIMS [12].
Statistical methods
The acquired data for all AES patients was initially vali-
dated, coded and entered in SPSS Statistics software ver-
sion 17.0 (IBM-SPSS, New York) for analysis. Differences
between clinical groups were compared using Student
independent samples t-tests (for Normally distributed
data), Mann-Whitney U-tests (for non-Normally distribu-
ted data) and Fisher Exact tests (for categorical data/pro-
portions). All clinical feature variables (with the exception
of all duration and numbers of episodes variables apart
from duration of fever) were entered into a forward step-
wise multiple logistic regression model to identify variables
independently associated with bad outcome or JE positive
status; multiple imputation methods (10 iterations) were
used to overcome problems of missing observations and
collinearity statistics were examined to ensure indepen-
dence of the predictor variables. The median age and num-
bers of AES cases were mapped using ArcGIS version 9.3
(Esri Ltd., California) software to show their distribution in
the different districts across Nepal in order to identify any
spatial patterns in infection dynamics. Statistical signifi-
cance was set at the conventional 5% level for all analyses.
Results
Baseline characteristics
A total of 225 children with acute encephalitis syndrome
(AES) were admitted to the two hospitals between January
1
st, 2006 and January 1
st, 2008. Forty (18%) of these
patients did not have any lumbar puncture (LP) results
available in their notes. These patients were analysed
separately.
Of the remaining 185 AES patients, 40 (22%) were diagnosed
with either bacterial (n = 39) or Plasmodium falciparum infec-
tion (n = 1). Eight of these patie n t sa l s oh a de l e v a t e da n t i - J E
virus titres (≥ 40 units) on serum IgM testing during acute ill-
ness. Since bacterial co-infection can change clinical features
and influence patient outcome, these patients were analysed
separately (Figure 1).
One hundred and forty five AES patients (145/
185;78%) were considered to have AES of suspected
viral aetiology. Forty-two of these patients (23%) were
confirmed as JE. Among the other 103 patients, 44
tested negative to JE using samples collected after the
ninth day of their illness and therefore were classified as
Non-JE. For the remaining 59 patients JE status was
unknown (Figure 1).
The majority of JE positive patients, 41/50 (82%), were
identified by serum testing positive for anti-JEV IgM
antibodies, with 31/41 (79%) identified by a single
serum sample. The other serum samples tested positive
in paired samples. The remaining 9 patients were diag-
nosed by testing positive for anti-JEV IgM antibodies in
the CSF.
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Page 3 of 12The majority of the non-viral AES patients were diag-
nosed with suspected bacterial meningitis based on a
raised cell count with a polymorph predominance and
raised protein in the CSF. The commonest identified
cause of infection was gram stain positive bacteria in
CSF.
Patients presented to Kanti Children’s (n = 208) or
Patan hospital (n = 17) from a wide range of outlying
districts from Kathmandu including the hill and moun-
tain districts. There were no marked differences in geo-
graphic distribution for the number of cases or age at
presentation among the different sub-groups of sus-
pected viral AES patients (Figure 2). Route of presenta-
tion to hospital was documented in 175 AES patients.
Self-referral was the commonest route of presentation,
reported by 96/175 (55%) of AES patients.
Figure 1 Flow diagram of Acute Encephalitis Syndrome patients based on aetiological classification. 225 children with Acute Encephalitis
Syndrome (AES) were identified. To analyse AES of different aetiologies only patients where LP results were available were taken forward (n =
185). Patients with non-viral aetiologies were analysed separately (n = 40). The remaining AES patients were classified as JE (n = 42) or AES of
unknown viral aetiology (n = 103) based on presence or absence of high anti-JE virus immunoglobulin titres. AES of unknown viral aetiology
was further sub-classified into Non-JE (n = 44) and JE Status Unknown (n = 59) based on presence or absence of low or negative anti-JE virus
immunoglobulin titres.
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Outcome at discharge was recorded for 183/185 patients
where LP results were available and 38/40 patients with-
out LP results. Among the patients without LP results,
seventeen (45%) had a bad outcome; 10 (26%) died and
a further 7 (18%) had neurological sequelae at discharge.
Among the AES patients with non-viral infection, 38/
40 (95%) had an outcome at discharge recorded. Five
(13%) had a bad outcome; 2 died and a further 3 had
neurological sequelae at discharge. All 8 patients with
bacterial and JE co-infection exhibited complete recov-
ery at discharge. The one patient with P.falciparum
infection recovered completely.
Among the AES patients with suspected viral infec-
tion, 45/145 (31%) had a bad outcome; 8 died and 37
had neurological sequelae at discharge. Among the sub-
set of confirmed JE patients 20/42 (48%) had a bad out-
come; 4 died and 16 had neurological sequelae (Table
1).
A significantly higher proportion of patients without
LP results died compared to those where LP results
were available (10/38 [26%] versus 10/183 [5%]; P <
0.001). Similarly, the proportion of patients with bad
outcome were higher among patients without LP results
(17/38 [45%] versus 51/183 [28%]; P = 0.053). Exclusion
of the patients without LP results may have influenced
outcome within the AES groups. To help address this
issue, an additional analysis was undertaken, whereby
patients without LP results were classified into AES
categories based on their hospital discharge diagnosis
supported by their JE serological results. The patients
contributed to all AES groups. Each AES category
exhibited a higher rate of bad outcome. There were no
significant changes in the proportion of patients with
bad outcome between groups (Table 1).
A significantly higher proportion of patients with AES
of suspected viral aetiology had a bad outcome com-
pared to AES patients with a non-viral infection (45/145
[31%] versus 5/38 [13%]; P = 0.039). A significantly
higher proportion of JE patients exhibited a bad out-
come compared to AES patients of unknown viral
aetiology (20/42 [48%] versus 25/103 [24%]; P = 0.01). A
similar trend was observed when JE patients were com-
pared to Non-JE patients, with a higher proportion of JE
patients exhibiting a bad outcome (20/42 [48%] versus
12/44 [27%]); P = 0.07; Table 1).
Prognostic features associated with bad outcome at
discharge
Multiple parameters were associated with bad outcome
at discharge for both AES cases of suspected viral aetiol-
ogy (n = 145) and confirmed JE (n = 42) (Table 2). In
both groups, bad outcome was associated with a longer
duration of fever prior to admission, a lower Glasgow
coma score, a focal neurological deficit, older patient
age and higher weight at admission.
Figure 2 Map of residence district for Acute Encephalitis Syndrome patients of suspected viral aetiology. Panel A, All AES patients of
suspected viral aetiology; Panel B, JE patients; Increasing depth of shading within a district indicates a higher number of AES patients were
admitted from this district. Unshaded districts indicate no patients were admitted from this district. Increasing circle diameter within a district
indicates AES patients of an older (median) age were admitted. Kathmandu is labelled on the map.
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Suspected viral aetiology Non-viral aetiology
Outcome AES of suspected viral aetiology Confirmed JE AES of unknown viral aetiology Non-JE JE Status Unknown Bacterial (n = 37)* P.f. (n = 1)
Lp status +Lp -Lp Both +Lp -Lp Both +Lp -Lp Both +Lp -Lp Both +Lp -Lp Both +Lp -Lp Both
Patient No. 145 35 180 42 85 0 103 27 130 44 12 56 59 15 74 38 34 1
Good 100
(69)
19
(54)
119
(63)
22
(52)
3
(37.5)
25
(50)
78
(76)
16
(60)
94
(72)
22
(73)
8
(66)
40
(71)
46
(78)
8
(53)
54
(73)
33
(87)
2(
66)
35
(85)
Bad 45
(31)
§
16
(46)
61
(37)
§
20
(48)
‡¶
5
(62.5)
25
(50)
‡¶Δ
25
(24)
¶
11
(40)
36
(28)
¶
12
(27)
4
(33)
16
(29)
¶Δ
13
(22)
7
(47)
20
(27)
5
(13)
§‡
1
(33)
6
(15)
§‡
Neurol.
Sequelae
37
(25)
7
(20)
44
(24)
16
(38)
3
(37.5)
19
(38)
21
(20)
4
(15)
25
(19)
12
(27)
1
(8)
13
(23)
9
(15)
3
(20)
12
(16)
3
(8)
0
(0)
3
(7)
Died 8
(5)
9
(26)
17
(9)
4
(9.5)
2
(25)
6
(12)
4
(4)
7
(26)
11
(8)
0
(0)
3
(25)
3
(6)
4
(7)
4
(27)
8
(11)
2
(5)
1
(33)
3
(7)
Outcome at hospital discharge is presented for 2 main aetiological categories of Acute Encephalitis Syndrome (AES); suspected viral and non-viral. Based on JE serology, AES of suspected viral aetiology was split into
Confirmed JE and Unknown viral aetiology. The latter group was sub-categorised into Non-JE and JE status unknown. AES of non-viral aetiology included Bacterial and Plasmodium falciparum (P.f.) infection. Within
each category, patients were split into 3 groups based on availability of LP results; +Lp, those with LP results; -Lp, those without; Both, combining both +Lp and -Lp patients. Patients without LP results were
assigned to an AES group based on their discharge diagnosis and JE serological results. Patients with a bad outcome were sub-classified into those with neurological sequelae at discharge or those that died.
Number with (%) is presented. Significance was tested via Fisher’s Exact test.
* 38/40 patients with AES of Non-viral aetiology had an outcome recorded at discharge.
§ Significant difference between suspected viral and non-viral patients (P = 0.039 and P = 0.022 respectively for +Lp and Both groups).
‡Significant difference between JE and non-viral patients (P = 0.001 and P < 0.001 respectively for +Lp and Both groups).
¶Significant difference between JE and Unknown viral patients (P = 0.01 and P = 0.008 respectively for +Lp and Both).
ΔSignificant difference between JE and Non-JE patients in the Both group (P = 0.029).
A similar trend was observed for outcome between JE and Non-JE patients in the +Lp group (P = 0.074).
A higher frequency of death was consistently observed among -Lp patients compared to +Lp patients in each AES category.
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2To identify whether these features were independently
associated with bad outcome, these variables were
entered into a forward stepwise logistic regression model
separately for each patient group. For the larger group,
all AES of suspected viral aetiology, fever duration (P =
0.002), GCS (P < 0.001), and focal neurological deficit (P
= 0.001) were retained in the model for outcome. In JE,
fever duration (p = 0.007) and GCS (p = 0.020) were
again independently associated with bad outcome (but
not focal neurological deficit) together with age (P =
0.011).
To assess whether length of time from onset of illness
to hospital admission was a prognostic marker for bad
outcome, we used length of reported fever prior to
admission as a proxy marker. We selected a threshold of
7 days of fever prior to admission (Figure 3). We found
fever duration over 7 days was associated with a bad out-
come. Fever duration was reported in 142/145 (98%) of
patients with AES of suspected viral aetiology. Thirty-two
patients reported fever duration of more than 7 days
prior to admission. Of these, 19 had bad outcome and 13
had good outcome. The remaining 110 patients reported
a fever duration under 7 days, of which 23 had bad out-
come and 87 had good outcome (19/32 [59%] versus 23/
110 [20%]; P < 0.001). This indicates that AES patients
who present with a prolonged fever prior to hospital
admission have an increased risk of having a bad out-
come at discharge (Relative Risk = 2.8 [95% confidence
interval: 1.6 - 4.4]).
Among the JE patients, a reported fever duration of
more than 7 days prior to admission was again linked to
a significantly higher rate of bad outcome compared to
those who presented with a shorter duration of fever (9/
11 [82%] versus 11/31[36%]; P = 0.013). Among patients
with AES of non-viral aetiology, prolonged duration of
fever prior to admission was also linked to a higher rate
of bad outcome (2/6 [33%] versus 3/22 [14%]; P = 0.28).
Of the treatments given to AES patients of suspected
viral aetiology, mannitol and phenytoin were more fre-
quently prescribed among those with a bad outcome
compared to those with a good outcome; 27/61 (44%)
versus 19/119 (16%), P < 0.001 for mannitol; 23/61
(38%) versus 12/119 (10%), P < 0.001 for phenytoin, in
bad and good outcome patients respectively.
Table 2 Clinical features for JE and AES patients of suspected viral aetiology by outcome
Confirmed JE (n = 42) AES suspected viral aetiology (n = 145)
Clinical Features at admission Bad Good p-value Bad Good p-value
No. patients 20 22 45 100
Age (years) 10 (1-14) [20] 4.5 (1-13) [22] 0.004 8 (1-14) [45] 6 (1-14) [97] 0.005
Number of males 5 (25) [20] 11 (50) [22] 0.121 13 (29) [45] 30 (31) [98] 1.000
Fever prior to admission (days)* 7 (3-13) [20] 5 (1-12) [22] 0.010 7 (1-14) [45] 5 (1-13) [100] < 0.001
Altered sensorium 17 (85) [20] 13 (59) [22] 0.091 39 (89) [44] 55 (56) [98] < 0.001
Duration of altered sensorium (days) 2 (1-5) [13] 2 (1-3) [10] 0.839 2 (1-7) [30] 1 (1-4) [43] 0.009
Modified Glasgow coma score* 11 (5-15) [20] 14 (7-15) [22] 0.001 11 (3-15) [44] 14 (4-15) [98] < 0.001
Focal neurological deficit 9 (50) [18] 4 (18) [22] 0.046 17 (40) [43] 7 (7) [100] < 0.001
Any seizure prior to admission 10 (77) [13] 15 (75) [20] 1.000 24 (77) [31] 67 (83) [81] 0.591
Episodes of seizure prior to admission
‡ 2 (1-12) [9] 2 (1-4) [14] 0.723 2 (1-12) [19] 2 (1-7) [48] 0.034
Neck stiffness 14 (82) [17] 9 (45) [20] 0.040 29 (71) [41] 49 (54) [91] 0.086
Vomiting 10 (71) [14] 13 (87) [15] 0.390 29 (81) [36] 47 (86) [55] 0.573
Days of vomiting prior to admission
Δ 3 (2-10) [8] 3 (1-7) [9] 0.400 3.5 (1-12) [26] 2 (1-8) [37] 0.019
Weight (kgs) 19.5 (9-30) [20] 13 (1-26) [22] 0.017 19 (4-35) [45] 15 (1-70) [90] 0.040
Axillary temperature (°C) 38.1 (36.7-40.0) [20] 37.8 (36.7-39.4) [20] 0.170 37.8 (36.1-40.0) [44] 37.8 (36.1-40.0) [86] 0.256
Pulse rate
(beats per min.)
101 (52-150) [20] 104 (76-130) [22] 0.905 106 (52-160) [44] 110 (64-170) [96] 0.972
Respiratory rate (breaths per min.) 28 (20-50) [20] 36 (20-80) [22] 0.064 28 (3-60) [45] 30 (16-90) [92] 0.158
Death prior to discharge 4 (20) [20] 0 (0) [22] — 8 (18) [45] 0 (0) [100] —
Neurological sequelae at discharge 16 (80) [20] 0 (0) [22] 37 (82) [45] 0 (0) [100]
Treatment
Phenytoin 6 (30) [20] 0 (0) [22] 0.007 18 (40) [45] 8 (8) [100] < 0.001
Phenobarbitone 5 (25) [20] 3 (14) [22] 0.445 10 (22) [45] 10 (10) [100] 0.067
Dexamethasone 6 (30) [20] 4 (18) [22] 0.477 12 (27) [45] 22 (22) [100] 0.533
Mannitol 6 (30) [20] 2 (9) [22] 0.123 19 (42) [45] 15 (15) [100] 0.001
Median (range) or Number (%) [number of patients]. Significance of difference between groups by Fisher’s Exact test or Mann-Whiney U test.
‡: patients with one
or more seizures before admission only
Δ: patients with vomiting prior to admission only * Parameters identified as independently associated with bad outcome
in both AES groups.
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and AES of suspected non-JE viral aetiology
Confirmed JE cases were compared to AES cases of
unknown viral aetiology (Non-JE and JE status unknown).
As the latter group also contained patients that did not
have a confirmed negative test for JE, a further analysis
was undertaken comparing JE against Non-JE cases.
The rates of many clinical features and laboratory para-
meters were similar on admission between confirmed JE,
confirmed Non-JE and JE-status unknown (Tables 3 and
4). Importantly, the rates of many recorded neurological
features were comparable between the patient groups.
There were no significant differences in prevalence of an
altered sensorium at admission, depth or duration of
coma, frequency, duration or type of seizures between
patient groups. However, there was a significantly higher
prevalence of patients presenting with focal neurological
deficits at admission among confirmed JE patients com-
pared to AES cases of unknown viral aetiology (13/40 ver-
sus 11/103; P = 0.005; Relative Risk = 3.0 [95% confidence
interval: 1.4-6.7]). Among AES patients of suspected viral
aetiology, presence of a focal neurological deficit at admis-
sion had a positive predictive value of 32% (sensitivity
54%) for JE. Absence of a focal neurological deficit at
admission had a negative predictive value of 89% (specifi-
city 77%) for the patient not having JE.
JE patients presented with a lower body weight (15.25
versus 20 Kg; P = 0.031), and a higher respiratory rate (30
versus 28 breaths per minute; P = 0.003) compared to con-
firmed non-JE patients. With the caveat that serum urea,
creatinine and electrolytes were measured in only 25 AES
patients of suspected viral aetiology, there was a trend for
higher serum urea (15 versus 8.9 mmol/L; P = 0.27),
sodium (137 versus 133 mmol/L; P = 0.09) and potassium
(4.3 versus 3.9 mmol/L; P = 0.21) among JE compared to
Non-JE patients (Table 4[13]). These parameters again
showed a non-significant trend for higher median values
among JE patients compared to AES patients of unknown
viral aetiology (Table 4).
Both weight and respiratory rate, which were signifi-
cantly different among JE patients compared to Non-JE
patients, are in part dependent on patient age. To further
dissect the influence of these parameters, age, weight and
respiratory rate were entered into a stepwise logistic
regression model. Only raised respiratory rate (P = 0.011)
was retained.
Admission patterns also differed between JE and Non-
JE patients. JE patients demonstrated a clear peak in
hospital admissions rates in the months immediately fol-
lowing the rainy seasons each year (August and Septem-
ber in 2006-2007). Non-JE patients didn’td e m o n s t r a t e
any clear seasonal variation in hospital admission rates
(Figure 4).
Discussion
This study demonstrates that patients with AES of sus-
pected viral aetiology, either where JE was confirmed or
where viral aetiology remained unknown, were signifi-
cantly more likely to have a bad outcome compared to
AES patients with bacterial or malaria infection.
Appropriately, JE surveillance is a health priority in
Nepal. However, public health and clinical teams should be
aware that patients with AES of unknown viral aetiology
also have a high risk of morbidity and mortality. Further-
more, since there are up to 3 times more Nepali children
with AES of unknown viral aetiology than proven JE, a bad
outcome among the former group impacts on a larger
number of children Therefore, identification and optimiz-
ing management of patients with AES should also be a
priority.
Figure 3 Fever duration prior to admission organised by
outcome among AES patients of suspected viral aetiology.
Panel A, All AES patients of suspected viral aetiology; Panel B, JE
patients, X-axis; fever duration (1-14 days), Y-axis; Number of
patients that presented to hospital at each day of fever duration (1-
24), Solid bar shading; number of patients who exhibited a bad
outcome at discharge, Hatched bar shading; number of patients
who exhibited a good outcome at discharge.
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Clinical features Confirmed JE AES unknown viral aetiology (n = 103) AES bacterial aetiology (n = 39)
Non-JE JE Status Unknown Bact. Inf. Bact. and JEV+
No. patients (% AES patients (n = 184
†)) 42(23) 44(24) 59(32) 31(17) 8(4)
Age (years) 7(1-14)[42] 8(1-14)[44] 4.5(1-13)[56] 4.5(1-12)[31] 3.5(1-10)[8]
Number of males 16(38)[42] 16(36)[44] 16(27)[59] 11(35)[31] 8 [100][8]
Fever prior to admission
(days)
5.5(1-13)[42] 6(2-14)[44] 5(1-12)[59] 5(1-13)[30] 5 (1-16)[7]
Altered sensorium 30(71)[42] 29(69)[42] 35(60)[58] 13(43)[31] 5 [63][8]
Duration of altered sensorium (days) 2(1-5)[23] 2(1-7)[24] 1(0-5)[27] 3(1-4)[9] 1(1-1.1)[3]
Modified Glasgow coma score 12(5-15)[42] 14(4-15)[44] 14(3-15)[59] 15(4-15)[30] 12(7-15)[8]
Focal neurological deficit 13(32)[40] 7(16)[44] 4(7)[59] 2(12.5)[16] 1(33)[3]
Any seizure prior to admission 25(76)[33] 25(78)[32] 42(89)[47] 21(75)[28] 4(50)[8]
Generalised seizure prior to admission 22(96)[23] 22(92)[24] 35(92)[38] 21(95)[22] 3(38)[8]
Focal seizure prior to admission 1(4)[23] 0(0)[24] 1(3)[38] 0(0)[22] 0(0)[8]
Episodes of seizure prior to admission 2(2-12)[23] 1(1-7)[17] 2(1-9)[27] 1.5(1-7)[18] 1.2 (1-1.5)[2]
Est. duration of longest seizure (mins.) 6(3-60)[16] 6(3-60)[16] 5(4-60)[12] 5(1-5)[3] 10(10-10.2)[2]
Neck stiffness 23(62)[37] 27(66)[41] 28(52)[54] 18(58)[31] 5(63)[8]
Vomiting 23(79)[29] 24(83)[29] 29(88)[33] 18(78)[23] 3(38)[8]
Days of vomiting prior to admission 3(1-10)[18] 4(1-11)[21] 2(1-12)[25] 3.5(1-10)[12] 1.2(1-2)[5]
Weight (Kg) 15.25(1-30)[42] 20(9-70)[38]* 14(1-60)[55] 15(1-60)[29] 11(1-25)[8]
Axillary temperature (°C) 37.8(36.7-40)[40] 37.2(36.1-40)[38] 37.8(36.1-40)[52] 37.8(36.7-41.1)[29] 38.9(37.8-39.4)[7]
Pulse rate
(beats per min.)
101(52-150)[42] 100(69-160)[41] 110[78-170)[57] 100(70-160)[28] 120(72-130)[7]
Systolic BP (mmHg) 96(50-120)[17] 93(78-130)[20] 100(9-110)[14] 100(80-140)[11] 100(90-110)[3]
Dystolic BP (mmHg) 60(20-90)[17] 60(10-100)[20] 60(0-100)[15] 70(50-110)[11] 70(60-80)[3]
Respiratory rate
(breaths per min.)
30(20-80)[42] 28(16-60)[40]** 30(3-90)[55] 34(20-50)[30] 34(24-40)[7]
Median (range) or Number (%) [number of patients]. Significance of difference between groups by Fisher’s Exact test or Mann-Whiney U test.
†Single patient with
Plasmodium infection not presented. Significant difference between JE and Non-JE patients; P = 0.031*; P = 0.003**
Table 4 Laboratory parameters at admission for 5 categories of Acute Encephalitis Syndrome
Laboratory parameters Confirmed JE AES unknown viral aetiology (n = 103) AES bacterial aetiology (n = 39)
Non-JE JE Status Unknown Bact. Bact. and JEV+
No. patients 42 44 59 31 8
Blood
Hemoglobin (g/L) 112(80-190)[37] 116(80-140)[37] 112(60-200)[55] 116(30-460)[24] 112(81-120)[7]
Total leucocyte count (x10
9/L) 10.9(2.46-33)[41] 9.6(1.8-25.8)[40] 12.5(4.0-9.8)[56] 9.5(1.48-110)[27] 12 (1.96- 190)[7]
Polymorphs (proportion) 0.73(0.08-0.92)[41] 0.72(0.3-0.96)[39] 0.75(0.16-0.93)[56] 0.77(0.50-0.92)[27] 0.82(0.63-0.95)[7]
Lymphocytes (proportion) 0.21(0.08-0.82)[41] 26(0.04-0.7)[39] 0.24(0.06-0.84)[54] 0.21(0.08-0.4)[27] 0.18(0.05-0.34)[7]
Blood sugar (mmol/L) 5.1(2.2-12.1)[13] 5.1(2.2-10.3)[20] 4.4(3.3-7.5)[26] 6.5(3.7-13.3)[4] 7.8(6.4-8.2)[5]
Urea (mmol/L)
† 15(6.8-17.1)[5] 8.9(1.4-18.9)[10] 10.3(0.7-20.3)[10] nr 9.6(5.3-21.4)[3]
Creatinine (μmol/L) 44.2(8.8-88)[3] 53.4(8.8-71.6)[11] 53.0(8.8-79.6)[13] nr 64.5(35- 80)[3]
Sodium (mmol/L) 137(127-160)[12] 133(126-146)[17] 133(109-149)[20] 139(129-148)[9] 137 (134- 139)[2]
Potassium (mmol/L) 4.3(3-5)[12] 3.9(3-5)[17] 3.95(2-5)[20] 3.8(3.5-4.9)[9] 3.8 (3.6- 3.9)[2]
Cerebrospinal fluid
Total leucocyte count (x10
9/L) 0.043(0-0.6)[42] 0.041(0-0.83)[44] 0.035(0-0.54)[59] 0.14(0-1.4)[31]* 0.07 (0-0.4)[8]
Polymorphs (proportion) 0.1(0-1)[41] 0.3(0-1)[42] 0.26(0-1)[57] 0.7(0-1)[30]* 0.8(0-0.9)[8]
Lymphocytes (proportion) 0.5(0-1)[41] 0.38(0-1)[42] 0.6(0-1)[57] 0.3(0-1)[30] 0.15(0-1)[8]
Protein (g/L) 0.4(0-1.2)[39] 0.4(0-1.5)[40] 0.4(0.1-1.5)[53] 0.65(0.2-1.5)[30]* 0.1(0.04-5.8)[8]
Sugar (mmol/L) 3.3(1.4-5.7)[41] 3.3(0.9-5.6)[43] 3.3(1.7-6.1)[53] 2.1(1.1-3.8)[30]* 2.1(0.7- 3.3)[8]
Median (range) or Number (%) [number of patients]. Significance of difference between groups by Fisher’s Exact test or Mann-Whiney U test. *Significant (P <
0.01) difference between patients within AES of suspected viral aetiology and AES of bacterial aetiology; nr, not recorded;
†normal range for urea (newborn to 16
years): 1.1-6.4 mmol/L [13].
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patients with bacterial or malaria infection is likely to
reflect the availability and effective use of antibiotics and
anti-malaria treatment to reduce morbidity among these
patients.
AES patients without LP results exhibited a significantly
higher rate of death. The finding is likely to reflect lumbar
punctures being undertaken less frequently on children
who were critically ill. The finding highlights that restrict-
ing analyses to patients where LP results are available can
lead to an underestimation of the frequency of death and
bad outcome linked to AES.
Interestingly, the study has identified that the number of
days of fever (reflecting number of days of illness) the
patient experienced prior to hospital admission is a prog-
nostic indicator of bad outcome in both patients with AES
of unknown viral aetiology and JE. When analysis was
applied to AES patients of bacterial aetiology no significant
association was identified. Antibiotic use in the commu-
nity may reduce fever duration prior to hospital admission
in patients with bacterial infection and may confound the
association between fever duration and bad outcome. In
contrast, antibiotics would have limited impact on fever
duration during viral infection.
Shorter duration of illness (or fever) prior to admission
has previously been associated with good outcome
among children for a range of diseases [8]. What is
striking about our finding is that there is no specific
treatment for JE or AES of suspected viral aetiology, yet
attending hospital earlier in the illness course appears to
be of benefit. The findings would suggest that hospital
admission and the supportive management received
there improves outcome.
Patients with impaired consciousness are often unable
to drink themselves. Consequently, dehydration and
metabolic acidosis may complicate AES [14]. Dehydra-
tion and acidosis would fit the significantly lower body
weight and higher respiratory rate observed among JE
compared to Non-JE patients. A previous prospective
survey of JE management identified that fluid supple-
mentation was associated with a positive influence on
outcome [15]. Although appropriate fluid provision is a
delicate balance when managing brain injury [16,17],
one possible explanation of the positive influence of
hospital admission may be that patients receive fluid
support in hospital during the illness.
Given the commonest reported mode of presentation
was self-referral, the focus on hastening patient atten-
dance would lie with improving patient awareness of the
features of AES and encouraging families to attend hos-
pital promptly. Further research is needed to understand
the factors that underlie families’ health-seeking beha-
viours when a child is ill.
As shown previously, a low Glasgow coma scale (GCS)
and/or a focal neurological deficit at hospital admission
were independent clinical markers of bad outcome
among children with AES [18].J Ep a t i e n t sf r e q u e n t l y
exhibit raised intra-cranial pressure, brain herniation
syndromes [5] and focal brain lesions on neuro-imaging
studies [19], explaining the preponderance of focal neu-
rolgical deficits in this group.
In line with previous reports, mannitol was prescribed
significantly more frequently among AES patients who
exhibited a bad outcome [15]. Interestingly, a rando-
mized clinical trial of mannitol among children with
raised raised ICP secondary to cerebral malaria (another
cause of non-traumatic brain injury) did not identify any
beneficial effect [20]. A similar study would help clarify
whether mannitol is a useful supportive treatment in
AES [21].
JE patients exhibited an increased respiratory rate com-
pared to Non-JE patients. Furthermore, JE patients who
exhibited a high respiratory rate were associated with a
good outcome, while those with a lower respiratory rate
were associated with a bad outcome. This pattern can be
observed during evolution of many complications,
including metabolic acidosis,p n e u m o n i a ,a c u t ef l a c c i d
paralysis (involving the inter-costal muscles) or brain
damage, where there may be an intial compensatory rise
in respiratory rate followed by a fall when the body
decompensates.
Figure 4 Monthly admission numbers for Acute Encephalitis
Syndrome (AES) patients of suspected viral aetiology. X-axis;
month of admission, Yaxis; Number of patients admitted to hospital
each month, Solid bar shading; number of JE patients, Hatched bar
shading; number of Non-JE patients, Dotted bar shading; number of
patients where JE Status unknown.
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syndrome - paroxysmal autonomic instability with dysto-
nia (PAID)[22]. Patients with this brain injury syndrome
exhibit intermittent agitation, diaphoresis, hyperthermia,
hypertension, tachycardia, tachypnea, and extensor postur-
ing. All of these signs overlap with features reported in
both JE and AES. PAID may exist among AES patients.
As a descriptive analysis this study cannot distinguish
cause from consequence. Consequently although several
clinical features and interventions appear linked with
outcome, this study is unable to determine whether
these parameters are causal. Similarly, as a retrospective
study it is limited by the breadth and quality of informa-
tion available in the hospital notes. More detailed infor-
mation on acid-base status would help discriminate
between respiratory and metabolic causes of tachypnea.
Similarly, more systematic measurement of urea and
electrolytes and additional indicators of fluid balance
would help assess the influence of fluid support on out-
come. Based on their discharge diagnosis, the AES
patients without LP contributed to all AES groups.
However, a prospective study with a more systematic
investigation of pathogen aetiology is warranted to con-
firm these findings.
Conclusions
Nepali children with AES of suspected viral aetiology,
either where JE is confirmed or where the aetiology
remains unknown, exhibit a high rate of death and
morbidity.
One of the more striking findings from the study was
the association between long duration of fever prior to
admission and bad outcome. If patients with AES of
suspected viral aetiology, including those with confirmed
JE, attend hospital early they are more likely to make a
full recovery. Despite no specific treatment for JE or for
patients with AES of suspected viral aetiology, the cur-
rent management in Nepal can limit the development of
neurological sequelae. The findings imply that family
members, primary and community health care workers
should be aware of AES and seek early referral for
appropriate and potentially life-saving, supportive
management.
Despite many comparable neurological features
between JE patients and patients with AES of unknown
viral aetiology, significantly more JE patients exhibited a
bad outcome. This, in part, may reflect the higher pro-
portion of JE patients that presented with a focal neuro-
logical deficit at hospital admission.
Further research is needed to understand the factors
that underlie bad outcome in AES and JE, including a
more systematic investigation of the influence of sup-
portive measures.
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